A single-institution phase II study indicated that combination chemotherapy using UFT (tegafur and uracil) plus cisplatin (Platinol) in patients with non-small-cell lung cancer was active with less host toxicity than other cisplatin-
Kozo Yoshimori, MD
Advertisement
Articles by Kozo Yoshimori, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative
2
From Conference to Practice: Top 5 Takeaways From EHA 2026
3
57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers
4
3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
5